life scienc tool diagnost
bottom line ep ahead consensu dgx ep
exceed higher revenu profit partial
off-set factor line re-affirmed
guidanc call ep vs previou consensu
reflect like conservat rais ep
reflect beat encourag build volum momentum
expand network access pt move ebitda
higher view
volum price profit impress revenu
forecast stronger volum vs estimate organ
sequenti acceler reflect volum captur partial off-set
unexpect capit contract loss bp time
better plan favor test mix diminish
headwind patient concess bp gross margin fell bp
bp plan admin expens declin bp bp better
forecast on-going invigor initi take hold net/net
compar ebitda margin deterior bp bp plan
flow million facilit million share repurchas
million dividend
today better volum price experi manag point
acceler trend loss certain low margin
region capit contract southeast new datapoint
emphas minim revenu ep impact overal traction clearli
build new in-network relationship also remain optimist
dgx prospect unh pln albeit like time
beyond date light still view recent
contract shift post-pama world spur consolid
across industri benefit lead consolid risk
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
provid diagnost test inform
price jul rate neutral target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
better fundament perform could come faster
organ growth gain in-network statu
sentiment could drive upsid target price blue sky
scenario
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
 close
organ growth robust revenu growth forecast
sequenti acceler trend notabl volum growth remain
robust despit bp headwind loss sever region capit contract
open renew southeast rel larger volum contract
margin inher low one dgx larg competitor unnam potenti
lh bid aggress term caveat note face bp
headwind time holiday embed expect
experi increment headwind vitamin test reimburs shift
aetna previous expect unquantifi essenti lap previou
headwind prescript drug monitor one contract transit
manag larg attribut organ growth strength increas access
increment million in-network member contract bcb new
jersey bcb georgia also note volum growth across major
health plan custom term cadenc contract shift experienc
initi healthi start year new contract januari driven educ
effort sequenti improv june continu build
throughout year line previou commentari remind estim
three new contract repres billion revenu opportun aim
captur share in-lin current market posit within
independ lab segment also note continu experi partial offset
loss non-exclus aetna contract dynam embed
expect manag note recent stabil even recoveri
volum loss
rev/accn better also highlight revenue/access ahead
estim repres improv experi
owe part favor mix lose low margin capit region
busi note year year declin attribut anticip reimburs
pressur relat pama bp headwind y/i well patient concess
bp dynam diminish lap prior year headwind along
effort improv collect
materi updat unh pln like traction build time
also start august provid refer member out-of-network lab need
complet on-line approv process remind effect juli enter
unitedhealthcar prefer laboratori network pln note also
implement strategi lower rate hospital-bas provid align
independ anoth potenti favor dynam importantli continu
discuss payer similar value-bas contract dynam could also
steer greater volum lower cost clinic laboratori drive broader industri
industri consolid number fundament chang clinic market place
underway includ pama reimburs chang payor focu lab spend
transpar drive consolid long-await dynam manag
note potenti materi decision-mak relev industri constitu
build meaning beyond
addit recent enter lab servic agreement cathol
servic long island pursuant agreement manag laboratori
equip suppli procur process six hospit core lab cancer
center infus center well provid refer test allow focu
core oper financi detail disclos view deal
encourag continu
hospit strategi capit effici
collabor vs comment call activ dialogu
number system
 prefer lab network
compani mention price
labcorp america lh
